Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Pacific Biosciences of California stock

Own Pacific Biosciences of California stock in just a few minutes.

Pacific Biosciences of California, Inc is a diagnostics & research business based in the US. Pacific Biosciences of California shares (PACB) are listed on the NASDAQ and all prices are listed in US Dollars. Pacific Biosciences of California employs 412 staff and has a trailing 12-month revenue of around 0.00.

How to buy shares in Pacific Biosciences of California

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – PACB – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Pacific Biosciences of California share price

Use our graph to track the performance of PACB stocks over time.

Pacific Biosciences of California shares at a glance

Information last updated 2021-04-23.
52-week range$3.13 - $53.69
50-day moving average $32.04
200-day moving average $26.66
Wall St. target price$51.50
PE ratio 179.2941
Dividend yield N/A (0%)
Earnings per share (TTM) $0.17

Buy Pacific Biosciences of California shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee Signup bonus
Sofi Invest
$0
Stocks, ETFs, Cryptocurrency
N/A
0%
A free way to invest in stocks, ETFs and crypto.
Robinhood
$0
Stocks, Options, ETFs
$0
0%
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Interactive Brokers
$0
Stocks, Bonds, Options, Mutual funds, ETFs, Currencies
$0 + $0.65/contract, $1 minimum
0%
N/A
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
Webull
$0
Stocks, Options, ETFs
$0
0%
Get one free stock valued between $2.50 and $250 when you open an account, one more with a deposit
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.
Public
$0
Stocks, ETFs
N/A
$0 per month
N/A
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Pacific Biosciences of California stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Is Pacific Biosciences of California under- or over-valued?

Valuing Pacific Biosciences of California stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Pacific Biosciences of California's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Pacific Biosciences of California's P/E ratio

Pacific Biosciences of California's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 179x. In other words, Pacific Biosciences of California shares trade at around 179x recent earnings.

That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.

Pacific Biosciences of California financials

Revenue TTM $78.9 million
Gross profit TTM $32.6 million
Return on assets TTM -21.88%
Return on equity TTM 15.06%
Profit margin 37.27%
Book value $1.75
Market capitalisation $5.8 billion

TTM: trailing 12 months

Shorting Pacific Biosciences of California shares

There are currently 12.9 million Pacific Biosciences of California shares held short by investors – that's known as Pacific Biosciences of California's "short interest". This figure is 12.4% up from 11.5 million last month.

There are a few different ways that this level of interest in shorting Pacific Biosciences of California shares can be evaluated.

Pacific Biosciences of California's "short interest ratio" (SIR)

Pacific Biosciences of California's "short interest ratio" (SIR) is the quantity of Pacific Biosciences of California shares currently shorted divided by the average quantity of Pacific Biosciences of California shares traded daily (recently around 4.4 million). Pacific Biosciences of California's SIR currently stands at 2.91. In other words for every 100,000 Pacific Biosciences of California shares traded daily on the market, roughly 2910 shares are currently held short.

However Pacific Biosciences of California's short interest can also be evaluated against the total number of Pacific Biosciences of California shares, or, against the total number of tradable Pacific Biosciences of California shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Pacific Biosciences of California's short interest could be expressed as 0.07% of the outstanding shares (for every 100,000 Pacific Biosciences of California shares in existence, roughly 70 shares are currently held short) or 0.0704% of the tradable shares (for every 100,000 tradable Pacific Biosciences of California shares, roughly 70 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Pacific Biosciences of California.

Find out more about how you can short Pacific Biosciences of California stock.

Pacific Biosciences of California share dividends

We're not expecting Pacific Biosciences of California to pay a dividend over the next 12 months.

Pacific Biosciences of California share price volatility

Over the last 12 months, Pacific Biosciences of California's shares have ranged in value from as little as $3.13 up to $53.69. A popular way to gauge a stock's volatility is its "beta".

PACB.US volatility(beta: 1.18)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Pacific Biosciences of California's is 1.1842. This would suggest that Pacific Biosciences of California's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).

Pacific Biosciences of California overview

Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing systems to resolve genetically complex problems. The company provides PacBio's Systems, which conduct, monitor, and analyse biochemical sequencing reactions; consumable products, including single molecule real-time (SMRT) cells; and various reagent kits designed for specific workflow, such as template preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases. It also offers binding kits, such as modified DNA polymerase used to bind SMRTbell libraries to the polymerase in preparation for sequencing; and sequencing kits comprise reagents required for on-instrument, real-time sequencing, including the phospholinked nucleotides. The company serves research institutions; commercial laboratories; genome centers; clinical, government, and academic institutions; genomics service providers; pharmaceutical companies; and agricultural companies. It markets its products through a direct sales force in North America and Europe, as well as through distribution partners in Asia, Europe, the Middle East, Africa, and Latin America. Pacific Biosciences of California, Inc.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site